Luciana de M Leite1, Paulo G Bergerot2, Aldo L A Dettino1, José Augusto R1, Stenio de C Zequi3,4, Maria Nirvana da C Formiga1,4. 1. Departamento de Oncologia Médica, AC Camargo Cancer Center, São Paulo, SP, Brasil. 2. Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 3. Departamento de Urologia Oncológica, AC Camargo Cancer Center, São Paulo, SP, Brasil. 4. Instituto Nacional de Ciência e Tecnologia em Oncogenômica e Inovação Terapêutica, AC Camargo Cancer Center, São Paulo, SP, Brasil.
Abstract
BACKGROUND: Tyrosine kinase inhibitors (TKI) and immunotherapy improved survival in metastatic renal cell carcinoma (mRCC). Disparities in treatment access are present in healthcare systems globally. The aim of this study was to analyze survival outcomes of mRCC patients treated with first-line TKIs in the public (PHS) and private (PrS) health system in a Brazilian Cancer Center. MATERIALS AND METHODS: Records from all mRCC patients treated with first-line TKIs from 2007-2018 were reviewed retrospectively. Categorial variables were compared by Fisher's exact test. Survival was estimated by Kaplan-Maier method and survival curves were compared using the log-rank test. Prognostic factors were adjusted by Cox regression model. RESULTS: Of the 171 eligible patients, 37 (21.6%) were PHS patients and 134 (78.4%) were PrS patients. There were no difference in age, gender, or sites of metastasis. PHS patients had worse performance status (ECOG ≥2, 35.1% vs. 13.5%, p=0.007), poorer risk score (IMDC poor risk, 32.4% vs. 16.4%, p=0.09), and less nephrectomies (73% vs. 92.5%, p=0.003) than PrS patients. Median lines of therapy was one for PHS versus two for PrS patients (p=0.03). Median overall survival (OS) was 16.5 versus 26.5 months (p=0.002) and progression-free survival (PFS), 8.4 versus 11 months (p=0.01) for PHS and PrS patients, respectively. After adjusting for known prognostic factors on multivariate analysis, PHS patients still had a higher risk of death (HR: 1.61, 95% CI: 1.01-2.56, p=0.047). CONCLUSION: Patients with mRCC treated via the PHS had worse overall survival, possibly due to poorer prognosis at presentation and less drug access. Copyright® by the International Brazilian Journal of Urology.
BACKGROUND: Tyrosine kinase inhibitors (TKI) and immunotherapy improved survival in metastatic renal cell carcinoma (mRCC). Disparities in treatment access are present in healthcare systems globally. The aim of this study was to analyze survival outcomes of mRCC patients treated with first-line TKIs in the public (PHS) and private (PrS) health system in a Brazilian Cancer Center. MATERIALS AND METHODS: Records from all mRCC patients treated with first-line TKIs from 2007-2018 were reviewed retrospectively. Categorial variables were compared by Fisher's exact test. Survival was estimated by Kaplan-Maier method and survival curves were compared using the log-rank test. Prognostic factors were adjusted by Cox regression model. RESULTS: Of the 171 eligible patients, 37 (21.6%) were PHS patients and 134 (78.4%) were PrSpatients. There were no difference in age, gender, or sites of metastasis. PHS patients had worse performance status (ECOG ≥2, 35.1% vs. 13.5%, p=0.007), poorer risk score (IMDC poor risk, 32.4% vs. 16.4%, p=0.09), and less nephrectomies (73% vs. 92.5%, p=0.003) than PrSpatients. Median lines of therapy was one for PHS versus two for PrSpatients (p=0.03). Median overall survival (OS) was 16.5 versus 26.5 months (p=0.002) and progression-free survival (PFS), 8.4 versus 11 months (p=0.01) for PHS and PrSpatients, respectively. After adjusting for known prognostic factors on multivariate analysis, PHS patients still had a higher risk of death (HR: 1.61, 95% CI: 1.01-2.56, p=0.047). CONCLUSION:Patients with mRCC treated via the PHS had worse overall survival, possibly due to poorer prognosis at presentation and less drug access. Copyright® by the International Brazilian Journal of Urology.
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Laurence Albiges; Tom Powles; Michael Staehler; Karim Bensalah; Rachel H Giles; Milan Hora; Markus A Kuczyk; Thomas B Lam; Börje Ljungberg; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Axel Bex Journal: Eur Urol Date: 2019-08 Impact factor: 20.096
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Kathrin Strasser-Weippl; Yanin Chavarri-Guerra; Cynthia Villarreal-Garza; Brittany L Bychkovsky; Marcio Debiasi; Pedro E R Liedke; Enrique Soto-Perez-de-Celis; Don Dizon; Eduardo Cazap; Gilberto de Lima Lopes; Diego Touya; Joāo Soares Nunes; Jessica St Louis; Caroline Vail; Alexandra Bukowski; Pier Ramos-Elias; Karla Unger-Saldaña; Denise Froes Brandao; Mayra E Ferreyra; Silvana Luciani; Angelica Nogueira-Rodrigues; Aknar Freire de Carvalho Calabrich; Marcela G Del Carmen; Jose Alejandro Rauh-Hain; Kathleen Schmeler; Raúl Sala; Paul E Goss Journal: Lancet Oncol Date: 2015-10 Impact factor: 41.316
Authors: Kiran Gupta; Jeffrey D Miller; Jim Z Li; Mason W Russell; Claudie Charbonneau Journal: Cancer Treat Rev Date: 2008-03-04 Impact factor: 12.111
Authors: J Connor Wells; Igor Stukalin; Craig Norton; Sandy Srinivas; Jae Lyun Lee; Frede Donskov; Georg A Bjarnason; Haru Yamamoto; Benoit Beuselinck; Brian I Rini; Jennifer J Knox; Neeraj Agarwal; D Scott Ernst; Sumanta K Pal; Lori A Wood; Aristotelis Bamias; Ajjai S Alva; Ravindran Kanesvaran; Toni K Choueiri; Daniel Y C Heng Journal: Eur Urol Date: 2016-06-16 Impact factor: 20.096
Authors: Martin C S Wong; William B Goggins; Benjamin H K Yip; Franklin D H Fung; Colette Leung; Yuan Fang; Samuel Y S Wong; C F Ng Journal: Sci Rep Date: 2017-11-16 Impact factor: 4.379